Scott Gottlieb Biography and Net Worth

Dr. Gottlieb has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He was elected Chairman of the Board of Directors in March 2025. His work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.

Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai.